Kymera Therapeutics DEF 14A: Executive Compensation Details
Ticker: KYMR · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1815442
| Field | Detail |
|---|---|
| Company | Kymera Therapeutics, Inc. (KYMR) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, corporate-governance, proxy-statement
TL;DR
Kymera's DEF 14A is out, showing exec comp details for FY24. Focus on equity awards.
AI Summary
Kymera Therapeutics, Inc. filed a DEF 14A on April 29, 2025, detailing executive compensation and other corporate governance matters. The filing covers the fiscal year ending December 31, 2024, and includes information on equity awards granted and vested for both principal executive officers (PEO) and non-PEO/NEO members. Specific financial details regarding the fair value of these awards are presented.
Why It Matters
This filing provides transparency into how Kymera Therapeutics compensates its top executives, which can influence investor perception and decisions regarding the company's leadership and financial strategy.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and corporate governance, not indicating new financial risks.
Key Players & Entities
- Kymera Therapeutics, Inc. (company) — Filer
- 20250429 (date) — Filing Date
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit proxies from shareholders for an upcoming annual meeting or to provide information about executive compensation and other corporate governance matters.
What fiscal year does this Kymera Therapeutics DEF 14A filing primarily cover?
This filing primarily covers the fiscal year ending December 31, 2024.
What type of compensation details are highlighted in this filing?
The filing highlights details regarding equity awards granted and vested, including their fair value, for principal executive officers (PEO) and non-principal executive officers/named executive officers (non-PEO/NEO).
When was this DEF 14A filed with the SEC?
This DEF 14A filing was filed with the SEC on April 29, 2025.
What is the Standard Industrial Classification (SIC) code for Kymera Therapeutics?
The Standard Industrial Classification (SIC) code for Kymera Therapeutics is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Kymera Therapeutics, Inc. (KYMR).